Navigation Links
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
Date:11/2/2011

NATICK, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export (SINE) for various cancers.  The Company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

Michael Kauffman, MD, PhD, Karyopharm's CEO, remarked, "This funding shows the confidence our investors have in our progress and platform. With these additional resources, we are able to move our oral clinical SINE compound for oncology into Phase I studies in both hematologic and solid tumor malignancies. The oral bioavailability and preliminary tolerability of the compounds allow us to investigate these agents for indications outside of cancer, including autoimmune, inflammatory and viral disorders.  We look forward to bringing the first SINE therapeutic to patients with cancer in the coming year."

Karyopharm is the leader in the development of nuclear transport modulators for the treatment of cancer, autoimmune, dermatologic, and viral diseases. These SINEs act by forcing the nuclear localization of major tumor suppressor and growth regulatory proteins, causing selective death of cancer cells while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown activity in a variety of animal models.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of smal
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
6. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
7. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
8. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
9. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
10. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced that it will hold its 2015 Annual Meeting ... Because the expected date for the Annual ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... generation webinar series is designed to introduce ... and inform users and partners of platform ... features and benefits; empowering users in their ... and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Mylan Inc. (Nasdaq: MYL ) today announced ... it holds a 71.2% controlling interest, has been selected ... projects as the primary supplier of five antiretroviral (ARV) ... has been selected as the primary supplier of seven ...
... DIEGO, April 20 Trius Therapeutics, Inc. today announced ... H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, ... group of anti-infective thought leaders. Dr. Batts is ... and the Chief of Infectious Diseases at its ...
... -- Data presented at 100th Annual Meeting of the ... 19 Researchers from Dendreon Corporation (Nasdaq: ... Treatment and Early Cancer Treatment) or P-11 Phase 3 ... responses that are durable and can be maintained following ...
Cached Biology Technology:Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 2Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 3Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 4Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 5
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... student at Rensselaer Polytechnic Institute has learned very quickly ... medicine go down. In fact, with his invention, the ... most important and complex molecules in the human body, ... communicate with one another. Graduating senior Jeffery Martin has ...
... Mireya Correa, staff scientist at the Smithsonian Tropical Research ... Panama, received the Jos Cuatrecasas Medal for Excellence in ... the National Museum of Natural History and the United ... Botanical Symposium held at the museum. , Jos ...
... gas used as an agricultural pesticide, was introduced in ... and increase fruit yields. Agricultural production nurseries around the ... plants for export and domestic sales. In 2000, the ... and in 2005 MB was banned in the United ...
Cached Biology News:Undergrad has sweet success with invention of artificial Golgi 2Undergrad has sweet success with invention of artificial Golgi 3Smithsonian scientist receives 2008 Medal for Excellence in tropical botany 2Alternatives to ozone-depleting pesticide studied 2
... ,Kit containing Dermal Fibroblasts (Mouse/BalbC) and ... a long-term culture, and is guaranteed to ... growth from the date supplied, when used ... mouse/BalbC, embryonic day 18.5 ,Applications: ...
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... are designed for protein pull-down ... sphingosine binding proteins. An order ... of agarose beads with 10 ... the terminus of the alkyl ...
... Immunogen: Synthetic Peptide: M(1) E ... P G P P T M D L ... from mouse cells.,PA1-072 has been successfully used in ... antibody detects an ~86 kDa protein representing Mint3 ...
Biology Products: